Skip to main content
. Author manuscript; available in PMC: 2015 Nov 1.
Published in final edited form as: Gynecol Oncol. 2014 Aug 23;135(2):208–212. doi: 10.1016/j.ygyno.2014.08.018

Table 1.

Patient Characteristics by Tumor Histology

N squamous-cell carcinoma
N = 1489
adeno- & adenosq. carcinoma
N = 182
Test Statistic
Age (years) 1671 46.5 (38.8–55.9) 46.0 (54.6–39.4) P = 0.561
Race/Ethnicity 1671 P = 0.0772
  White 59.9% (892) 64.8% (118)
  Black 24.3% (362) 15.9% (29)
  Hispanic, other 12.2% (182) 15.4% (28)
  Asian 3.6% (53) 3.8% (7)
Performance status 1671 P = 0.4592
  normal, asymptomatic 70.9% (1055) 75.3% (137)
  symptomatic, ambulatory 25.4% (378) 21.4% (39)
  symptomatic, in bed 3.8% (56) 3.3% (6)
Tumor size (cm) 1659 6.0 (5.0–8.0) 6.0 (5.0–7.0) P < 0.0011
Tumor size (cm) 1659 P = 0.0052
  < 5.0 15.8% (234) 22.5% (41)
  5.0–6.0 18.8% (278) 24.7% (45)
  6.0–7.5 38.9% (575) 35.2% (64)
  ≥ 7.5 26.4% (390) 17.6% (32)
FIGO stage 1671 P = 0.1022
  IB2 20.0% (298) 27.5% (50)
  IIB 47.1% (702) 47.3% (86)
  IIIA 1.3% (20) 1.6% (3)
  IIIB 28.6% (426) 21.4% (39)
  IVA 2.9% (43) 2.2% (4)
Tumor grade (differentiation) 1671 P < 0.0012
  well 5.5% (82) 14.3% (26)
  moderate 65.3% (972) 37.9% (69)
  poor 26.9% (400) 46.2% (84)
  not graded 2.4% (35) 1.6% (3)
Hydronephrosis 1671 P = 0.62
  none 88.9% (1324) 91.2% (166)
  unilateral 8.8% (131) 6.6% (12)
  bilateral 2.3% (34) 2.2% (4)
Parametrial involvement 1671 P = 0.1082
  none 21.7% (323) 28.6% (52)
  unilateral 46.3% (689) 42.9% (78)
  bilateral 32.0% (477) 28.6% (52)
Pelvic nodes 1671 P = 0.0332
  positive 10.3% (154) 15.9% (29)
  negative 62.8% (935) 63.2% (115)
  unknown 26.9% (400) 20.9% (38)

b (a–c) represent the lower quartile a, the median b, and the upper quartile c for continuous variables.

N is the number of non–missing values.

Numbers after percents are frequencies.

Tests used:

1

Wilcoxon test;

2

Pearson test